1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Discovery and Development of Oral Small-molecule Direct-acting Antivirals Targeting Viruses of Pandemic Potential" is currently closed and not accepting applications.
Discovery and Development of Oral Small-molecule Direct-acting Antivirals Targeting Viruses of Pandemic Potential is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). This funding opportunity supports focused antiviral drug discovery efforts directed toward key viral pathogens or viral families and/or common drug targets or mechanisms-of-action.
The goal is to generate a more substantial pool of antiviral lead series and candidate drugs with the potential to quickly address future viral outbreaks or pandemics. Of particular interest is the identification and development of oral small-molecule drug candidates with suitable safety profiles for broad use in the outpatient setting.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small business concerns. Fast-Track and Direct-to-Phase II proposals will be accepted. Confirm the full requirements in the official notice before applying.
The current listing shows phase I: $500,000 for up to 1 year; Phase II: $2,000,000 for up to 3 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was October 18, 2024, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Discovery and Development of Oral Small-molecule Direct-acting Antivirals Targeting Viruses of Pandemic Potential is funded by National Institute of Allergy and Infectious Diseases (NIAID). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleThe ReVAMPP network funds vaccine and monoclonal antibody research across five virus families. Here is who won, what the prototype-pathogen strategy means, and how to position for the next round.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article